Review of regulatory recommendations for orphan drug submissions in the netherlands and scotland: focus on the underlying pharmacoeconomic evaluations-Reference-Cited by-同舟云学术

Review of regulatory recommendations for orphan drug submissions in the netherlands and scotland: focus on the underlying pharmacoeconomic evaluations

Published:2010-08 Issue:9 Volume:32 Page:1651-1661
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Vegter Stefan,Rozenbaum Mark H.,Postema Roelien,Tolley Keith,Postma Maarten J.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference8 articles.

1. Orphan drug development across Europe: Bottlenecks and opportunities;Heemstra;Drug Discov Today.,2008

2. Decisionmaking by healthcare payers;Levine;Respir Med.,2002

3. Orphan drugs and the NHS: Should we value rarity?;McCabe;BMJ.,2005

4. Commissioning for rare diseases: View from the frontline;Burls;BMJ.,2005

5. Ethical issues in funding orphan drug research and development;Gericke;J Med Ethics.,2005

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Access to medicines - a systematic review of the literature;Research in Social and Administrative Pharmacy;2020-09

2. Öffentliche Lenkung und Preisbegrenzung für Orphan-Drugs;Monatsschrift Kinderheilkunde;2018-06-20

3. Common drug review recommendations for orphan drugs in Canada: basis of recommendations and comparison with similar reviews in Quebec, Australia, Scotland and New Zealand;Orphanet Journal of Rare Diseases;2018-01-30

4. A review of international coverage and pricing strategies for personalized medicine and orphan drugs;Health Policy;2017-12

5. Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia;Health Policy;2016-10